Tevogen Bio Holdings Inc. (TVGN)
Tevogen Bio Holdings Inc. operates in the Biotechnology industry of the Healthcare sector, headquartered in Warren, NJ, US. The stock last traded at $6.65, up 4.07% on the session, giving a market capitalisation of $27.7M. On trailing twelve-month figures it carries a trailing P/E of -1.14, a net margin of 0.0%. Its beta of 0.21 implies it has historically moved less than the broad market.
Tevogen Bio Holdings Inc. is a clinical-stage biotechnology firm dedicated to developing "off-the-shelf" precision T cell therapies for conditions across virology, oncology, and neurology. Its flagship experimental product, TVGN 489, is a precision T cell therapeutic engineered to address critical unmet needs in patients with acute-risk COVID-19, alongside a specific population experiencing long COVID. The company's operations are headquartered in Warren, New Jersey.
Tevogen Bio Holdings Inc. is most often compared with the following Healthcare names: